美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

AdvisorShares Psychedelics ETF

20.48

-0.7750-3.65%

成交量：2.08万

成交额：42.90万

市值：4,412.31万

市盈率：- -

高：21.10

开：21.10

低：20.41

收：21.25

52周最高：27.02

52周最低：15.63

股本：215.50万

流通股本：215.50万

量比：1.04

换手率：0.97%

股息：1.68

股息率：8.22%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

NRX制药旗下NRX Defense Systems获美国国防高级研究计划局1100万美元主承包合同，评估机器人磁刺激联合NRX-101治疗难治性抑郁症

BUZZ——美国股市动态-埃森哲、Arhaus、Alkermes

阿尔凯默斯宣布ALKS 7290治疗成人注意力缺陷多动障碍（ADHD）的1B期临床概念验证取得积极成果

Compass Pathways在2026年精神病学大会上于美国启动‘改变难治性抑郁症的旋律’项目，深化医疗专业人士认知

专家敦促美国食品药品监督管理局（FDA）为迷幻药物制定明确的安全和获取标准

Compass Pathways公布美国资助计划入选者，旨在推进Comp360获批后供应商培训项目

Compass Pathways 25毫克组在第52周实现MADRS平均降低13点，疗效持续至一年

Compass Pathways：Comp360在C部分的安防特性与此前阶段保持一致，无新增安全性发现

Compass Pathways发布COMP005三期试验52周开放标签顶线数据：Part C部分追加COMP360剂量，疗效持久性延长至一年

《柳叶刀·神经病学》刊发阿尔凯默斯Alixorexton治疗1型发作性睡病II期临床积极数据

NRX Pharmaceuticals（纳斯达克：NRXP）发布2026年第二季度财务业绩并更新公司动态；电话会议定于8月17日（周一）美东时间下午4：30召开

美银证券：中国CXO行业受惠生物科技融资强劲上调药明康德等目标价

NRX Pharmaceuticals迎来转机：FDA将在2026年8月6日会议后以最快周期审核认证

Compass Pathways携手美国退伍军人事务部，推进裸盖菇素临床研究

NRX Pharmaceuticals - 7月21日，NRXD获DARPA选中，就潜在SPARC-TMS临床试验资助进行谈判 - SEC文件披露

阿尔凯默斯Alixorexton长期扩展研究中期分析显示：对1型与2型发作性睡病成人患者日间觉醒维持改善效果

阿尔凯默斯 - Alixorexton在首次给药九个月后，于第24周在MWT和ESS上显示出持续改善

阿尔凯默斯与安尼尔终止授权仿制药供应协议

阿尔凯默斯与安尼尔协议终止后，无需承担罚金或额外义务——SEC文件披露

BUZZ——美国股市动态-特斯拉、英伟达、Rivian

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/PSIL/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":20.475,"timestamp":1791918718346,"preClose":21.25,"halted":0,"volume":20833,"delay":0,"changeRate":-0.03647058823529405,"floatShares":2154976,"shares":2154976,"eps":0,"marketStatus":"交易中","change":-0.775,"latestTime":"10-13 15:13:21 EDT","open":21.095,"high":21.1,"low":20.41,"amount":429030.343738,"amplitude":0.032471,"askPrice":20.68,"askSize":100,"bidPrice":20.21,"bidSize":1000,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":21.25,"sharesOutstanding":1184976,"nav":21.742,"aum":46852860.14,"dividendRate":0.082198,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":21.25,"preClose":21.25,"latestTime":"19:30 EDT","volume":40,"amount":841.73,"timestamp":1791847803489,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.041201,"impliedVol":0.3312,"impliedVolPercentile":0.4064},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2154976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.041201,"shares":2154976,"dividePrice":1.683,"high":21.1,"amplitude":0.032471,"preClose":21.25,"low":20.41,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":20.475,"committee":0.818182,"eps":0,"divideRate":0.082198,"volume":20833,"delay":0,"ttmEps":0,"open":21.095,"prevYearClose":17.17,"prevWeekClose":21.765,"prevMonthClose":22.5,"prevQuarterClose":22.5,"fiveDayClose":21.24,"twentyDayClose":24.5,"sixtyDayClose":24.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1171089399","title":"NRX制药旗下NRX Defense Systems获美国国防高级研究计划局1100万美元主承包合同，评估机器人磁刺激联合NRX-101治疗难治性抑郁症","url":"https://stock-news.laohu8.com/highlight/detail?id=1171089399","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171089399?lang=zh_cn&edition=fundamental","pubTime":"2026-09-30 19:01","pubTimestamp":1790766071,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc.（纳斯达克代码：NRXP）旗下NRX Defense Systems获得美国国防高级研究计划局（DARPA）价值1100万美元的主承包合同，将评估机器人磁刺激与NRX-101联合用于难治性抑郁症的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669168093","title":"BUZZ——美国股市动态-埃森哲、Arhaus、Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2669168093","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669168093?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:52","pubTimestamp":1789991558,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-埃森哲、Arhaus、Alkermes工作区中用于查询单只股票走势的搜索字符串：STXBZ《今日展望》通讯：https://refini.tv/3LI4BU7《晨间新闻简报》：https://refini.tv/3dKUyB8路透9月21日-周一，受人工智能类股领涨推动，华尔街期货走高；与此同时，油价下跌2%拖累国债收益率走低，因有迹象表明中东交战各方对达成和解持开放态度","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4S45D0SA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2381873111.SGD","BK4127","LU0265550946.USD","BK4108","CUE","HOOW","COIG","BK4534","BULU","LU1823568750.SGD","CRMX","MSST","FDIG","ROBN","HOOD","LU1366333091.USD","MST","LU1861220207.SGD","BK4168","BK4566","MTYY","SGXZ31699556.SGD","BK4585","BK4139","SG9999018857.SGD","HOOX","HOOZ","LU1116320737.USD","LU0545562505.USD","MEDX","LU0511384066.AUD","SG9999017495.SGD","SGXZ23171101.USD","PSKY","LU1235294995.USD","LU0175139822.USD","CRMU","MSTW","MSTX","BK4516","MSTU","MSDD","IE00BHPRN162.USD","BK4125","BK4533","LU0342679015.USD","MSTZ","LU0323239441.USD","MSOO","BK4595","LU0130517989.USD","FINX","LU0949170772.SGD","LU1201861249.SGD","LU1861217088.USD","IAI","IE00B7KXQ091.USD","ACN","LU1430594728.SGD","BK4213","BULL","LU0289961442.SGD","LU1989772923.USD","HOYY","COII","LU0323240290.USD","IE0004445015.USD","CRML","DAPP","BULG","IE00BFSS7M15.SGD","BK4547","BK4551","BK4112","LU1883839398.USD","FBT","BITQ","APED","LU1861559042.SGD","LU1894683264.USD","BLCK","GLND","COIX","IE00BJJMRY28.SGD","LU1585245621.USD","LU0868494617.USD","MSTR","SG9999014914.USD","IBRN","BK4561","07399","WBD","MSII","HOOG","07799","LU0265550359.USD","3SMI.UK","HK0000819398.USD","COYY","BKCH","LU0157215616.USD","LU1003077747.HKD","LU1989772840.SGD","BK4554","LU0081259029.USD","LU1116320901.HKD","CONI","LU0738911758.USD","HOOI","LU1506573853.SGD","LU0942090050.USD","HODU","09311","PSCH","LU0868494708.USD","BK4178","BK4588","BPAY","LU0130102774.USD","COIW","BK4598","SG9999014880.SGD","CONX","COIA","FIAT","LU1861558580.USD","SMI3.UK","IE00BJJMRX11.SGD","LU0545039389.USD","IMST","LU2133065610.SGD","HOOC","LU1894683348.USD","SG9999018865.SGD","LU1228905037.USD","SG9999014906.USD","GRML","IBLC","IE00BFSS8Q28.SGD","07311","CONL","LU2211815571.USD","WNTR","BK4596","COIO","CRPT","LU1032466523.USD","SG9999014898.SGD","MSTP","HOII","SMST","IE00BSNM7G36.USD","LU0553294199.USD","OWNB","MSTK","LU1228905540.USD","PSIL","07711","LU2596442595.SGD","ARHS","LU0289960550.SGD","COIN","SG9999004303.SGD","MSTY.UK","09399","BK4581","IE000M9KFDE8.USD","LU2360107671.USD","LU1046421795.USD","LU0648001328.SGD","ALKS","BK4539","CONY","HOOY","REXC","LU2247934214.USD","LU0477156953.USD","BK4600","MSTC","MSTY","BK4134","09799","09711","LMI3.UK","LU0980610538.SGD","LU0661504455.SGD","LU0149725797.USD","LU0289739343.SGD","BK4535","ICOI","3LMI.UK","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142420523","title":"阿尔凯默斯宣布ALKS 7290治疗成人注意力缺陷多动障碍（ADHD）的1B期临床概念验证取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1142420523","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142420523?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988473,"startTime":"0","endTime":"0","summary":"阿尔凯默斯今日披露了一项振奋人心的阶段性成果——其试验性药物ALKS 7290在针对成人注意力缺陷多动障碍的1B期临床研究中，成功达成了临床概念验证。这标志着该候选药物迈出了关键性的一步。该研究旨在评估ALKS 7290在成人ADHD患者群体中的安全性、耐受性及初步疗效信号。阿尔凯默斯表示，将基于这些数据，迅速推进ALKS 7290进入下一阶段临床研究，以更全面、深入地验证其疗效与长期安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","PSIL","ALKS","FBT","PSCH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111501056","title":"Compass Pathways在2026年精神病学大会上于美国启动‘改变难治性抑郁症的旋律’项目，深化医疗专业人士认知","url":"https://stock-news.laohu8.com/highlight/detail?id=1111501056","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111501056?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 18:31","pubTimestamp":1789468272,"startTime":"0","endTime":"0","summary":"在即将召开的2026年精神病学大会上，COMPASS Pathways plc正式宣布于美国市场推出全新倡议——“改变难治性抑郁症的旋律”。该项目的核心目标在于拓宽医疗保健专业人士对难治性抑郁症的理解边界，推动临床认知的迭代升级。在2026年精神病学大会这一汇聚全球精神健康领域顶尖专家的平台上，该项目无疑将占据重要位置。COMPASS Pathways此举，也标志着其在推动精神健康治疗创新道路上迈出了坚实一步，超越了药物研发本身，深入到医疗生态系统的神经中枢。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667962699","title":"专家敦促美国食品药品监督管理局（FDA）为迷幻药物制定明确的安全和获取标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667962699","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667962699?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 06:39","pubTimestamp":1789425555,"startTime":"0","endTime":"0","summary":"此次听证会是美国总统唐纳德·特朗普政府自4月  以来，为推动合格的迷幻药物项目  进入市场所开展的、历时数月的最新举措。发言者敦促研究人员收集有关月经周期、妊娠及产后状况、围绝经期、绝经期、激素水平及合并用药的数据，并警告称汇总结果可能会掩盖疗效或不良事件方面的差异。“FDA对安全性和有效性的评估……必须始终是未来任何临床应用的基础，”美国精神病学协会表示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4S4561NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139","BK4007","GHRS","DFTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100081863","title":"Compass Pathways公布美国资助计划入选者，旨在推进Comp360获批后供应商培训项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1100081863","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100081863?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 18:36","pubTimestamp":1789036568,"startTime":"0","endTime":"0","summary":"Compass Pathways正式揭晓了美国资助计划的获选名单。这项计划聚焦于Comp360产品在获得监管批准之后的供应商培训事宜。通过这一举措，公司希望为相关培训体系的搭建提供有力支持。入选的机构将在后续阶段发挥关键作用，协助推动培训内容的开发与实施。此次公布的名单标志着该计划进入实质性推进阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168737220","title":"Compass Pathways 25毫克组在第52周实现MADRS平均降低13点，疗效持续至一年","url":"https://stock-news.laohu8.com/highlight/detail?id=1168737220","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168737220?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 18:36","pubTimestamp":1788950183,"startTime":"0","endTime":"0","summary":"Compass Pathways的25毫克剂量组在第52周呈现出平均13分的MADRS评分降幅，且这一改善效果能够稳定维持长达一年之久。这一结果不仅彰显了治疗方案的持续有效性，也为其在长期临床应用中提供了有力佐证。疗效的持久性无疑成为该研究中最引人瞩目的亮点之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161980382","title":"Compass Pathways：Comp360在C部分的安防特性与此前阶段保持一致，无新增安全性发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1161980382","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161980382?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 18:33","pubTimestamp":1788950025,"startTime":"0","endTime":"0","summary":"Compass Pathways宣布，其核心候选药物Comp360在临床试验C部分的安防特性与此前的试验阶段呈现一致性，未观察到新的安全性问题。这一发现为药物的后续研发推进提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195512633","title":"Compass Pathways发布COMP005三期试验52周开放标签顶线数据：Part C部分追加COMP360剂量，疗效持久性延长至一年","url":"https://stock-news.laohu8.com/highlight/detail?id=1195512633","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195512633?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 18:31","pubTimestamp":1788949897,"startTime":"0","endTime":"0","summary":"COMPASS Pathways公司近日公布了其三期临床试验COMP005的52周开放标签顶线数据。结果显示，在Part C阶段，受试者接受额外一剂COMP360治疗后，疗效持续时间得以显著延伸——长达整整一年之久。COMPASS Pathways 此前已多次强调，COMP360 的长期疗效管理是其临床开发战略的核心关注点之一。业内分析人士指出，尽管开放标签数据在证据等级上不及随机对照试验，但长期随访数据对于注册审评及临床实践指导同样不可或缺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141245521","title":"《柳叶刀·神经病学》刊发阿尔凯默斯Alixorexton治疗1型发作性睡病II期临床积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245521","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141245521?lang=zh_cn&edition=fundamental","pubTime":"2026-08-25 06:31","pubTimestamp":1787610670,"startTime":"0","endTime":"0","summary":"《柳叶刀·神经病学》杂志近日正式发表了阿尔凯默斯旗下在研药物Alixorexton的Vibrance-1 II期临床研究数据。该研究聚焦于成年1型发作性睡病患者，结果令人振奋。这项研究结果在顶级医学期刊上的亮相，标志着阿尔凯默斯在睡眠障碍治疗领域迈出了坚实一步。Alixorexton作为一种新型治疗手段，其临床数据经过了严格的同行评审，最终获得权威刊物的认可。阿尔凯默斯公司表示，这些积极数据将进一步推动Alixorexton的研发进程，有望为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","PSIL","ALKS","MEDX","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124751817","title":"NRX Pharmaceuticals（纳斯达克：NRXP）发布2026年第二季度财务业绩并更新公司动态；电话会议定于8月17日（周一）美东时间下午4：30召开","url":"https://stock-news.laohu8.com/highlight/detail?id=1124751817","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124751817?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 19:01","pubTimestamp":1786964479,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals（纳斯达克股票代码：NRXP）今日正式披露了截至2026年6月30日的第二季度财务报告，并同步向市场通报了公司近期运营进展。\n根据公告，该公司已敲定将于2026年8月17日（星期一）美东时间下午4：30举行投资者电话会议，届时管理层将对季度业绩进行深度解读，并就未来发展路径与市场参与者展开交流。\n此番财报发布正值公司推进关键管线项目之际，市场对其现金消耗节奏、研发里程碑达成情况以及潜在的战略合作动向均投以密切关注。NRX Pharmaceuticals在神经科学及精神健康治疗领域的布局，将持续吸引投资者审视其价值主张。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美银证券：中国CXO行业受惠生物科技融资强劲 上调药明康德等目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","PSIL","IBRN","BBC","IDNA","XBIX","MEDI","FHLC","SMCO","BMED","CXO","APXH","02359","161027","SURI","603259","PSCH","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177674010","title":"NRX Pharmaceuticals迎来转机：FDA将在2026年8月6日会议后以最快周期审核认证","url":"https://stock-news.laohu8.com/highlight/detail?id=1177674010","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177674010?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 19:01","pubTimestamp":1786100476,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals（NRXP）迎来关键进展。美国食品药品监督管理局（FDA）已确认，将于2026年8月6日会议之后，采用最短可能的审批周期，对该公司提交的认证申请进行审查。这一安排意味着监管机构正以最高效率推进评估流程，有望大幅缩短该公司等待最终决定的漫长周期。对投资者而言，这一消息无疑为市场注入了新的变量与期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151539682","title":"Compass Pathways携手美国退伍军人事务部，推进裸盖菇素临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1151539682","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151539682?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 18:43","pubTimestamp":1786012989,"startTime":"0","endTime":"0","summary":"Compass Pathways正与美国退伍军人事务部展开合作，旨在共同推进一项针对裸盖菇素的临床研究。这项实验性研究标志着在精神健康治疗领域迈出了新的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131214117","title":"NRX Pharmaceuticals - 7月21日，NRXD获DARPA选中，就潜在SPARC-TMS临床试验资助进行谈判 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1131214117","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131214117?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 19:09","pubTimestamp":1784718553,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. 于7月21日在提交给美国证券交易委员会的文件中披露，其已获得美国国防高级研究计划局的遴选，将就一项潜在的SPARC-TMS临床试验资助项目展开谈判。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139560681","title":"阿尔凯默斯Alixorexton长期扩展研究中期分析显示：对1型与2型发作性睡病成人患者日间觉醒维持改善效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1139560681","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139560681?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 19:03","pubTimestamp":1783940600,"startTime":"0","endTime":"0","summary":"一项长期扩展研究的中期分析数据表明，阿尔凯默斯（Alkermes PLC）旗下药物Alixorexton在治疗成人1型与2型发作性睡病患者时，能够持续改善其日间觉醒状态。该分析结果揭示了该药物在延长治疗期间维持疗效的潜力，为患者提供了长期管理症状的新希望。研究聚焦于药物对核心症状——过度日间嗜睡的持续作用，评估了患者在扩展治疗阶段保持清醒能力的变化趋势。这一积极发现进一步支持了Alixorexton作为慢性神经疾病长期治疗方案的可能性，后续完整数据值得期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","MEDX","BK4139","ALKS","PSCH","FBT","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187620650","title":"阿尔凯默斯 - Alixorexton在首次给药九个月后，于第24周在MWT和ESS上显示出持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1187620650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187620650?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 19:03","pubTimestamp":1783940597,"startTime":"0","endTime":"0","summary":"阿尔凯默斯公司宣布，其候选药物Alixorexton在首次给药九个月后，于临床试验的第24周评估中，在维持清醒测试和嗜睡量表两项关键指标上均表现出持续性的改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","PSCH","FBT","IBRN","MEDX","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160787890","title":"阿尔凯默斯与安尼尔终止授权仿制药供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1160787890","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160787890?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 20:06","pubTimestamp":1783512380,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，阿尔凯默斯公司与其合作伙伴安尼尔公司已共同决定，自2026年7月6日起，终止双方此前达成的授权仿制药产品供应协议。\n这一变动标志着两家公司在该特定产品合作上的正式分道扬镳。协议的终止将影响相关仿制药未来的市场供应格局。文件披露了这一商业安排的调整，但未进一步阐述终止协议的具体原因或后续财务影响。\n市场参与者将密切关注此举对阿尔凯默斯业务管线及收入构成的潜在影响。同时，安尼尔公司的产品组合也可能因此次合作终止而面临调整。此次战略调整的长期影响，仍有待后续观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","FBT","PSIL","PSCH","BK4139","MEDX","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155767412","title":"阿尔凯默斯与安尼尔协议终止后，无需承担罚金或额外义务——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1155767412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155767412?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 20:06","pubTimestamp":1783512372,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件，阿尔凯默斯与安尼尔在协议终止后，双方均无需支付任何罚金，也无需履行进一步的义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","ALKS","FBT","IBRN","BK4139","PSCH","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982968","title":"BUZZ——美国股市动态-特斯拉、英伟达、Rivian","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982968","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982968?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 19:50","pubTimestamp":1783425015,"startTime":"0","endTime":"0","summary":"尽管三星交出了强劲的财报，但投资者仍在重新评估这场由人工智能驱动的涨势能否持续；与此同时，SpaceX股价在即将登陆纳斯达克100指数前出现回落。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4S4390ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4549","LU0225283273.USD","IE00BFSS8Q28.SGD","AIFD","IE00BKVL7J92.USD","LU2065169927.USD","LU0109391861.USD","SG9999014898.SGD","SG9999004303.SGD","BK4560","LU2047632596.USD","SOXY","LU1914381329.SGD","LU2168564495.EUR","IE00B775H168.HKD","LU1496350502.SGD","LU2360032135.SGD","LU0006306889.USD","LU0353189763.USD","LU0354030511.USD","NVD","LU1244550494.USD","WLDR","LU1035775433.USD","LU0251132253.USD","LU0053666078.USD","IE00B19Z9P08.USD","IE000Q6AESB8.SGD","LU0274383776.USD","LU2552382132.HKD","NJUL","LU1116320737.USD","NVDO","NVII","LU1046421795.USD","LU0203202063.USD","QMAR","LU0289739343.SGD","LU1720051017.SGD","LU2462591277.SGD","LU2125154935.USD","IE00BKDWB100.SGD","LU1066051811.HKD","07388","LU1974910355.USD","LU0266013472.USD","NET","SHOC","TSLG","IE00B4JS1V06.HKD","GPIQ","IE00BD6J9T35.USD","LU1935042488.USD","LU2097344431.USD","CMPS","LU2491050154.USD","LU0143551892.USD","TSYY","LU2505996681.GBP","LU0719512351.SGD","SQQQ","VT","LU1496350171.SGD","LU0323591593.USD","LU0048584097.USD","LU0054578231.USD","LU1778281490.HKD","LU0154236417.USD","LU1400636657.SGD","IE00BK4W5L77.USD","LU2028103732.USD","LU1551013425.SGD","TSLS","LU2290526834.HKD","IE00BQXX3F31.USD","IE00BK4W5M84.HKD","SNVD.UK","LU2264538146.SGD","LU2361044865.SGD","LU0965509283.SGD","LU2430703178.SGD","LU0096364046.USD","NVDS","LU0472753341.HKD","LU1934455277.USD","LU1989772840.SGD","LU1670756490.USD","LU1642822529.SGD","SG9999014906.USD","LU0308772762.SGD","METV","BK4007","LU1242518931.SGD","LU2750360997.AUD","LU2077746001.SGD","IE0034235303.USD","BK4596","HK0000306685.HKD","LU1935043023.USD","LU2236285917.USD","LU0072462426.USD","TSII","TSLL","LU0158827948.USD","LU0210528500.USD","LU0238689110.USD","NVD3.UK","ROM","LU0096362180.USD","LU2505996509.AUD","BK4516","BK4567","BK4116","ABFL","LU1823568750.SGD","HXC","SNDG","LU1202635105.USD","BK4170","LU0942090050.USD","SG9999015986.USD","09086","LU0158827781.USD","BK4527","TSLY","HK0000320223.HKD","09834","LU2125909916.SGD","LU2931357623.SGD","LU2125154778.USD","IE00BDCRKT87.USD","LU2237443382.USD","LU2462591350.SGD","LU0138981039.USD","QQQM","QQQ","TQQY","LU0985320562.USD","LU2471134879.HKD","SG9999017495.SGD","SNDU","NVDD","FCUS","LU2092627202.USD","LU0823434583.USD","SNDC","LU0823421416.USD","LU0823414478.USD","LU2089283258.USD","LU0211327993.USD","03034","LU0203345920.USD","LU2471134952.CNY","LU0708994859.HKD","LU2065171311.SGD","LU2750360641.GBP","LU1791710582.SGD","LU0820561818.USD","SG9999018865.SGD","LU0963586101.USD","LU0267386448.USD","BK4547","LU1066053197.SGD","LU0079474960.USD","NOCT","LU2746668461.USD","LU2756315318.SGD","LU2087625088.SGD","CHAT","HK0000819398.USD","BK4139","LU2087621335.USD","LU2462157665.USD","LU1934455863.HKD",".IXIC","09366","IE00B894F039.SGD","LU2063271972.USD","NVDL","USXF","03086","SOXQ","BK4141","BK4581","LU1791710400.SGD","LU2242649171.HKD","IE00BHPRN162.USD","IE00B19Z9505.USD","LU0494093205.USD","LU1992135399.USD","LU1323610961.USD","LU0011850046.USD","LU1145028129.USD","BK4529","IE0009G5SDU7.USD","LU0097036916.USD","LU2433249047.HKD","LU1037948541.HKD","IDRV","LU2552382058.USD","LU2023250504.SGD","LU0788109477.HKD","LU1852331112.SGD","SNXX","07366","NVDB","LU1153585028.USD","TSLQ","2NVD.UK","LU0689472784.USD","LU2054465674.USD","OPTZ","LU1880398554.USD","IE00B19Z9Z06.USD","LU2322448957.HKD","NJAN","LU0162691827.USD","IE00B3S45H60.SGD","LU0444973449.USD","LU1064131342.USD","LU2430703251.USD","IE00BJJMRY28.SGD","RULE","LU2543165471.USD","AGIO","LU1232071149.USD","LU1571399168.USD","IE000ITXATA3.USD","IE00BJTD4V19.USD","ARTY","LU0889565833.HKD","LU2756315664.SGD","NVDU","WDC","SMOG","BK4605","LU1868836914.USD","IE000W1ABFV2.USD","LU1804176565.USD","LU2360106780.USD","IE0009356076.USD","LU1951200564.SGD","LU2458330169.SGD","LU2381873111.SGD","LU1720051108.HKD","IE00BQXX3D17.EUR","LU3102509885.SGD","LU0882574139.USD","LU2361044949.HKD","LU2458330243.SGD","XDAT","SGXZ99366536.SGD","TMSL","LU2326559502.SGD","LU2294711713.HKD","LU1951198990.SGD","LU1880398471.USD","IXN","LU2506951792.HKD","LU2106854487.HKD","LU0965508806.USD","BK4579","LU2860962120.EUR","NVDY","IE00BJJMRX11.SGD","LU0069063385.USD","LU0124676726.USD","LU0320765059.SGD","LU2065170008.USD","IE0004445015.USD","LU0444971666.USD","BK4548","BK4543","LU1861127337.USD","LU1868836757.USD","LU1691799644.USD","SGXZ81514606.USD","LU0861579265.USD","LU0289961442.SGD","LU0466842654.USD","LU0157215616.USD","LU0081259029.USD","HK0000914686.HKD","LU1712237335.SGD","LU2357125470.USD","QDEC","LU1037948897.HKD","LU2213496289.HKD","SG9999002232.USD","LU2491049909.HKD","LU1935042215.USD","SGXZ51526630.SGD","SG9999002224.SGD","LU0061475181.USD","FDTX","LU1035773651.USD","LU2237443465.HKD","LU1366333091.USD","LU0215105999.USD","TSLW","NULC","LU0133085943.USD","TSDD","LU1670627923.USD","LU2108987350.USD","LU0557290698.USD","LU0323240290.USD","SG9999015945.SGD","TTEQ","FSMD","3NVD.UK","BK4555","BK4512","LU2125909247.SGD","SG9999014914.USD","LU2237957902.USD","TSLO","EFIV","LU0127658192.USD","LU0390134368.USD","TLA","LU0683600562.USD","SG9999015952.SGD","NVIW.SI","NVDQ","SNPE","LU2552382215.SGD","IE00BJTD4N35.SGD","IE0001KFT4U8.USD","BK4587","USD","LU1721428933.USD","LU2125909759.SGD","LU1066051498.USD","SG9999015341.SGD","LU0316494557.USD","IE00BN29S564.USD","LU2211815571.USD","LU1935043536.SGD","LU0061474705.USD","SNDK","09766","FAI","IE000YTNTUN2.SGD","LU0528227936.USD","SG9999014567.USD","LU2125909593.SGD","LU0094547139.USD","LU1989764664.SGD","LU1935042991.SGD","LU2413666699.HKD","SMHX","LU1400636574.HKD","IE00B3M56506.USD","LU1670628061.USD","LU1861559042.SGD","BK4585","NVDX","SG9999000418.SGD","PSIL","ANV","LU1366192091.USD","SCHM","LU1235294995.USD","07522","LU2286300806.USD","SG9999014559.SGD","SG9999015358.SGD","SGXZ31699556.SGD","BK4099","LU2083900584.USD","LU1119994496.HKD","LU2637965513.SGD","IE00BJLML261.HKD","LU2602419157.SGD","IE00B775SV38.USD","LU0347712357.USD","LU2111349929.HKD","SOXX","BK4612","LU0964807845.USD","07766","LU0417517546.SGD","LU2100268510.USD","LU0689626769.HKD","LU0310800379.SGD","IE00BQXX3C00.GBP","LU0345770308.USD","LU2089985449.USD","LU0056508442.USD","WISE","LU0823421333.USD","LU2403377893.USD","LU1803068979.SGD","LU2394011477.USD","BK4533","LU0072461881.USD","IE00BKPKM429.USD","XLK","IE00B4YYXB79.USD","SG9999014542.SGD","LU2237957811.SGD","LU0106261372.USD","LU0210533765.USD","BK4554","IE00B5949003.HKD","LU1645745479.HKD","LU2954938101.SGD","LU1992135472.HKD","TSLR","SNDQ","LU2097344357.USD","LU0234570918.USD","TEK","LU2452424414.USD","CNAV","LU2361045086.USD","AIPI","NVDA","IE0005OL40V9.USD","LU1839511570.USD","07261","IE00BMPRXQ63.HKD","IE00B19Z8X17.USD","LU0265550359.USD","LU2461242641.AUD","LU2463028550.USD","TSL","NVDS.UK","LU0057025933.USD","IE0004091025.USD","QQQG","LU0077335932.USD","PTF","HK0000532082.HKD","LIT","IE00BZ199S13.USD","NVDG","LU0310799852.SGD","LU0823411888.USD","LU1629891620.HKD","LU2244417387.USD","TSLP","LU1923622291.USD","07266","WANT","HK0000304797.USD","LU0868494708.USD","LU2237443622.USD","LU0820562030.AUD","LU0345768153.USD","02834","LU1861220033.SGD","LU1988902786.USD","LU1435385759.SGD","NDX","LU0109392836.USD","LU1429558221.USD","CNEQ","BK4511","LU0276348264.USD","LU2168564222.USD","LU0082616367.USD","LU0174119429.USD","LU1821325948.USD","LU0354030438.USD","TEST","LU0203347892.USD","SG9999015978.USD","LU0979878070.USD","LU2272731600.USD","SG9999014575.USD","LU2247934214.USD","DIPS","LU0820561909.HKD","TYLG","LU1267930730.SGD","CGGO","LU0345768740.USD","LU0170899867.USD","LU1718418525.SGD","LU2168564149.EUR","LU0198837287.USD","LU2360107168.USD","QQQA","IE0034235295.USD","IE00B19Z8W00.USD","LU0210536198.USD","IE00BWXC8680.SGD","LU2089284900.SGD","BK4574","NVDW","SPTE","LU2357305700.SGD","LU1989764748.USD","LU1244550221.USD","COWG","LU2191332357.HKD","07788","LU0256863902.USD","LU0070217475.USD","HK0000914660.USD","LU0640476718.USD","LU1814569148.SGD","LU2168563687.JPY","LU2249611893.SGD","LU2023251221.USD","LU2271345857.HKD","LU2242650005.HKD","TSLA","LU0353189680.USD","LU0823434740.USD","LU0029864427.USD","LU1066051225.USD","03455","BK4607","IE00B3SWFQ91.USD","HK0000320264.USD","LU0187121727.USD","LU0724617625.USD","IE00BFSS7M15.SGD","BK4503","IE0034235188.USD","LU1868836591.USD","LU2168564065.EUR","LU1674673691.USD","LU1917777945.USD","IE0003U64NQ7.SGD","LU1815336760.USD","BK4532","LFGY","SMH","CLOU","ILDR","LU0256863811.USD","LU0342679015.USD","SG9999018857.SGD","LU1548497426.USD","LU1400636491.USD","LU2592432038.USD","LU0006061336.USD","LU2430703095.HKD","LU2272731865.HKD","FDRV","ESUM","VGT","LU2896262040.SGD","QID","LU2322448791.USD","SG9999001424.SGD","LU2746668974.SGD","LU2023250330.USD","RIVN","FTEC","LU0476273544.USD","BK4604","CRSH","LU2413666426.HKD","LU0203201768.USD","LU0289960550.SGD","LU2456880835.USD","LU0345769631.USD","SCHA","LU1983260115.SGD","LU1084165304.USD","LU1868837136.USD","NAPR","LU1551013342.USD","LU0128525929.USD","IE00BZ1G4Q59.USD","BK4551","LU0265550946.USD","LU0787776722.HKD","LU1069347547.HKD","IE0004445239.USD","IE00BDRTCR15.USD","LU2272731782.SGD","LU0107464264.USD","LU1815333072.USD","LU2237443978.SGD","HK0000306701.USD","07568","LU0823414551.USD","LU2999663052.SGD","TSLZ","BK4592","LU0061474960.USD","LU1116320901.HKD","LU1861558580.USD","SGXZ23171101.USD","WDCX","BK4598","LU0642271901.SGD","LU0323239441.USD","LU1069344957.HKD","LU0080751232.USD","LU1242518857.USD","LU0943347566.SGD","BK4550","LU2420271590.USD","LU1861215975.USD","LU1316542783.SGD","LU0957791311.USD","LU2237438978.USD","LU0511384066.AUD","LU1934455194.USD","TSLI","BK4614","BK4534","BK4588","LU1127390331.HKD","LU2148611432.USD","NVYY","IE000KEQY171.SGD","LU0957808578.USD","STX","LU0175139822.USD","LU0345770993.USD","IETC","CRNX","LU0211328371.USD","IE00B7KXQ091.USD","LU0672654240.SGD","LU0965509101.SGD","RVNL","LU0786609619.USD","IE00B1BXHZ80.USD","LU1280957306.USD","LU2250418816.HKD","LU1633808545.USD","LU0345769128.USD","LU1267930573.SGD","JGRO","BK4613","NETG","TRFK","LU1261432733.SGD","LU0868494617.USD","LU0234572021.USD","LU1699723380.USD","NVD2.UK","TSLT","LU0965509010.AUD","LU2237443549.SGD","EGGY","LU2471134523.USD","LU1989772923.USD","IE00BMPRXN33.USD","IE00BSNM7G36.USD","NETX","SG9999014880.SGD","LU2092937148.SGD","LU2471134796.USD","LU2417539215.USD","QLD","LU2491050071.SGD","IE00B1XK9C88.USD","IE0004086264.USD","LU1923622614.USD","LU1244550577.SGD","HK0000304805.HKD","TQQQ","CLSE","LU1923623000.USD","LU2473716301.USD","GB00BDT5M118.USD","AGOX","LU2237443895.HKD","PSQ","IE00BYXW3230.USD","LU1267930490.SGD","LU2265009873.SGD","LU2487616109.SGD","QQQX","LU0708995401.HKD","LU1623119135.USD","TESL","LU1868837300.USD","LU0348723411.USD","BK4608","IE00BMPRXR70.SGD","LU2065171402.SGD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}